In particular, immune checkpoint blockade, which targets inhibitory receptors such as CTLA-4 and PD-1/PD-L1, has shown significant clinical benefit in specific cancer types such as melanoma and non-small cell lung cancer [3, 4]. This evidence concerns the gene PDCD1 and melanoma.